Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001359746 | SCV001555628 | uncertain significance | MHC class II deficiency | 2021-08-20 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with glycine at codon 161 of the CIITA protein (p.Ala161Gly). The alanine residue is weakly conserved and there is a small physicochemical difference between alanine and glycine. This variant is present in population databases (rs763457920, ExAC 0.003%). This variant has not been reported in the literature in individuals affected with CIITA-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001359746 | SCV002090694 | uncertain significance | MHC class II deficiency | 2020-03-04 | no assertion criteria provided | clinical testing |